

Third AACR International Meeting
Advances in Malignant Lymphoma:
Maximizing the Basic-Translational Interface for Clinical Application
In cooperation with the International Conference on Malignant Lymphoma (ICML)
In association with *Blood Cancer Discovery*
June 23-26, 2022 | Westin Copley Place | Boston, MA

Chairs:

Riccardo Dalla-Favera, Columbia University, New York, NY
Sonali M. Smith, University of Chicago, Chicago, IL


Cochairs:

Francesco Bertoni, Institute of Oncology Research, Bellinzona, Switzerland*
Alexey V. Danilov, City of Hope National Medical Center, Duarte, CA
Michael R. Green, The University of Texas MD Anderson Cancer Center, Houston, TX
Ari M. Melnick, Weill Cornell Medical College / Cornell University, New York, NY
Teresa Palomero, Columbia University, New York, NY
Margaret A. Shipp, Dana Farber Cancer Institute, Boston, MA
Christian Steidl, BC Cancer, Vancouver, BC, Canada
Karin Tarte, University of Rennes, Rennes, France

* - ICML Representative

[R] – REMOTE PRESENTATION

DO NOT INCLUDE IN ON-DEMAND PROGRAM



Third AACR International Meeting
Advances in Malignant Lymphoma:
Maximizing the Basic-Translational Interface for Clinical Application
In cooperation with the International Conference on Malignant Lymphoma (ICML)
In association with *Blood Cancer Discovery*
June 23-26, 2022 | Westin Copley Place | Boston, MA

THURSDAY, JUNE 23

Registration

12:00 pm-7:00 pm | America Ballroom Foyer

Welcome and Opening Keynote Session

3:00 pm-5:00 pm | America Ballroom North and Center

- | | |
|-----------|--|
| 3:00-3:10 | Welcome and Introduction of Keynote Speaker
Riccardo Dalla-Favera, Columbia University, New York, NY |
| 3:10-3:40 | Therapeutic vulnerabilities uncovered by B-cell/stromal crosstalk
Karin Tarte, University of Rennes, Rennes, France |
| 3:40-3:50 | Q&A / Discussion |
| 3:50-3:55 | Introduction of Keynote Speaker
Riccardo Dalla-Favera, Columbia University, New York, NY |

- | | |
|-----------|--|
| 3:55-4:25 | [R] - Integrating bispecific antibodies into lymphoma therapy
Adrian U. Wiestner, National Heart, Lung, and Blood Institute, Bethesda, MD |
| 4:25-4:35 | Q&A / Discussion |

- | | |
|-----------|------------------|
| 4:35-5:00 | Panel Discussion |
|-----------|------------------|

Break

5:00 pm-5:30 pm | America Ballroom Foyer

Third AACR International Meeting
Advances in Malignant Lymphoma:
Maximizing the Basic-Translational Interface for Clinical Application
In cooperation with the International Conference on Malignant Lymphoma (ICML)
In association with *Blood Cancer Discovery*
June 23-26, 2022 | Westin Copley Place | Boston, MA

Plenary Session 1: CAR-T

5:30 pm-7:00 pm | America Ballroom North and Center

Session Chair: Sattva S. Neelapu, The University of Texas MD Anderson Cancer Center, Houston, TX

- | | |
|-----------|--|
| 5:30-5:50 | Lessons from CD19 CAR T-cell therapy in B-cell non-Hodgkin lymphoma
Sattva S. Neelapu, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 5:50-5:55 | Q&A / Discussion |
| 5:55-6:15 | Anti-CD19 Chimeric Antigen Receptor T-cells in CLL: A decade in review
Jan Joseph Melenhorst, Cleveland Clinic Lerner Research Institute, Cleveland, OH |
| 6:15-6:20 | Q&A / Discussion |
| 6:20-6:40 | Challenge accepted: CAR-T cells for T-cell malignancies
Rayne H. Rouse, Baylor College of Medicine, Houston, TX |
| 6:40-6:45 | Q&A / Discussion |
| 6:45-7:00 | Panel Discussion |

Opening Reception

7:00 pm-9:00 pm | America Ballroom South

FRIDAY, JUNE 24

Breakfast

7:00 am-8:00 am | America Ballroom South

Special Session 1: Initial Treatment of DLBCL: Are We in a New Era?

7:30 am-8:30 am | America Ballroom North and Center

Session Chair: Laurie H. Sehn, BC Cancer, Vancouver, BC, Canada

- | | |
|-----------|---|
| 7:30-7:45 | Molecular classification of DLBCL: Utility and barriers to implementation
Grzegorz S. Nowakowski, Mayo Clinic College of Medicine and Science, Rochester, MN |
| 7:45-7:50 | Q&A / Discussion |
| 7:50-8:05 | Is there a new one-size-fits-all standard of care in DLBCL?
Laurie H. Sehn, BC Cancer, Vancouver, BC, Canada |
| 8:05-8:10 | Q&A / Discussion |
| 8:10-8:30 | Panel Discussion |

Third AACR International Meeting
Advances in Malignant Lymphoma:
Maximizing the Basic-Translational Interface for Clinical Application
In cooperation with the International Conference on Malignant Lymphoma (ICML)
In association with *Blood Cancer Discovery*
June 23-26, 2022 | Westin Copley Place | Boston, MA

Break

8:30 am-8:45 am | America Ballroom Foyer

Plenary Session 2: Evolution of Liquid Biopsies for Lymphoma

8:45 am-10:15 am | America Ballroom North and Center

Session Chair: Davide Rossi, Institute of Oncology Research, Bellinzona, Switzerland

8:45-9:05 Understanding the biology of classic Hodgkin lymphoma using circulating tumor DNA

Davide Rossi, Institute of Oncology Research, Bellinzona, Switzerland

9:05-9:10 Q&A / Discussion

9:10-9:30 Circulating tumor DNA profiling for noninvasive disease detection and MRD monitoring in patients with CNS lymphoma

Florian Scherer, University Medical Center Freiburg, Freiburg, Germany

9:30-9:35 Q&A / Discussion

9:35-9:55 [R] – Next generation methods for disease detection and characterization from circulating tumor DNA

David M. Kurtz, Stanford University Medical Center, Stanford, CA

9:55-10:00 Q&A / Discussion

10:00-10:15 Panel Discussion

Break

10:15 am-10:30 am | America Ballroom Foyer

Third AACR International Meeting
Advances in Malignant Lymphoma:
Maximizing the Basic-Translational Interface for Clinical Application
 In cooperation with the International Conference on Malignant Lymphoma (ICML)
 In association with *Blood Cancer Discovery*
 June 23-26, 2022 | Westin Copley Place | Boston, MA

Plenary Session 3: Germinal Center Biology

10:30 am-12:00 pm | America Ballroom North and Center

Session Chair: Riccardo Dalla-Favera, Columbia University, New York, NY

10:30-10:50	[R] – T cell help and B cell selection in germinal centers Gabriel D. Victora, The Rockefeller University, New York, NY
10:50-10:55	Q&A / Discussion
10:55-11:15	Human germinal center responses to vaccination Michela Locci, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
11:15-11:20	Q&A / Discussion
11:20-11:40	[R] - Lymphoma mutations in the evolution of pathogenic autoantibodies Joanne Reed, The Westmead Institute for Medical Research, Westmead, NSW, Australia
11:40-11:45	Q&A / Discussion
11:45-12:00	Panel Discussion

Lunch Available

12:00 pm-1:30 pm | America Ballroom South

Plenary Session 4: Epigenetics

1:30 pm-3:00 pm | America Ballroom North and Center

Session Chair: Laura Pasqualucci, Columbia University Irving Comprehensive Cancer Center, New York, NY

1:30-1:50	BAF complex deregulation in lymphoma Michael R. Green, The University of Texas MD Anderson Cancer Center, Houston, TX
1:50-1:55	Q&A / Discussion
1:55-2:15	Novel interactions between epigenetic regulators altered in B cell lymphoma Laura Pasqualucci, Columbia University Irving Comprehensive Cancer Center, New York, NY
2:15-2:20	Q&A / Discussion
2:20-2:40	How to leverage epigenetic therapeutic interventions in FL? Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, NY
2:40-2:45	Q&A / Discussion
2:45-3:00	Panel Discussion

Third AACR International Meeting
Advances in Malignant Lymphoma:
Maximizing the Basic-Translational Interface for Clinical Application
In cooperation with the International Conference on Malignant Lymphoma (ICML)
In association with *Blood Cancer Discovery*
June 23-26, 2022 | Westin Copley Place | Boston, MA

Break

3:00 pm-3:15 pm | America Ballroom Foyer

Plenary Session 5: Modeling for Pre-clinical

3:15 pm-4:45 pm | America Ballroom North and Center

Session Chair: Giorgio Inghirami, Weill Cornell Medicine, New York, NY

- | | |
|-----------|---|
| 3:15-3:35 | Pre-clinical investigation using patient-derived xenograft modeling of aggressive and indolent B-cell lymphomas
Abner Louissaint, Massachusetts General Hospital, Boston, MA |
| 3:35-3:40 | Q&A / Discussion |
| 3:40-4:00 | Modeling EZH2 mutant follicular lymphomas
Wendy Béguélin, Weill Cornell Medicine, New York, NY |
| 4:00-4:05 | Q&A / Discussion |
| 4:05-4:25 | Translational research on mantle cell lymphoma: From lab to clinic
Michael Wang, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 4:25-4:30 | Q&A / Discussion |
| 4:30-4:45 | Panel Discussion |

Poster Session / Reception

5:00 pm-7:00 pm | America Ballroom South

Third AACR International Meeting
Advances in Malignant Lymphoma:
Maximizing the Basic-Translational Interface for Clinical Application
In cooperation with the International Conference on Malignant Lymphoma (ICML)
In association with *Blood Cancer Discovery*
June 23-26, 2022 | Westin Copley Place | Boston, MA

SATURDAY, JUNE 25

Breakfast

7:00 am-8:00 am | America Ballroom South

Special Session 2: Mantle Cell Lymphoma

7:30 am-8:30 am | America Ballroom North and Center

Session Chair: Francesco Bertoni, Institute of Oncology Research, Bellinzona, Switzerland

7:30-7:45 Dynamic changes in gene mutational landscape with preservation of core mutations in mantle cell lymphoma

Mariusz A. Wasik, Fox Chase Cancer Center, Philadelphia, PA

7:45-7:50 Q&A / Discussion

7:50-8:05 [R] - Targeting SOX11 in mantle cell lymphoma

Samir Parekh, Icahn School of Medicine at Mount Sinai, New York, NY

8:05-8:10 Q&A / Discussion

8:10-8:30 Panel Discussion

Break

8:30 am-8:45 am | America Ballroom Foyer

Plenary Session 6: DLBCL: Genomics Toward Precision Therapy

8:45 am-10:15 am | America Ballroom North and Center

Session Chair: Riccardo Dalla-Favera, Columbia University, New York, NY

8:45-9:05 Leveraging functional and structural genomics for precision medicine

James D. Phelan, National Cancer Institute, Bethesda, MD

9:05-9:10 Q&A / Discussion

9:10-9:30 Understanding lymphoma biology and improving classification through comprehensive sequencing

Ryan D. Morin, Simon Fraser University, Vancouver, BC, Canada

9:30-9:35 Q&A / Discussion

9:35-9:55 Pervasive hypermutation of super-enhancers dysregulates oncogene expression in DLBCL

Riccardo Dalla-Favera, Columbia University, New York, NY

9:55-10:00 Q&A / Discussion

10:00-10:15 Panel Discussion

Third AACR International Meeting
Advances in Malignant Lymphoma:
Maximizing the Basic-Translational Interface for Clinical Application
In cooperation with the International Conference on Malignant Lymphoma (ICML)
In association with *Blood Cancer Discovery*
June 23-26, 2022 | Westin Copley Place | Boston, MA

Break

10:15 am-10:30 am | America Ballroom Foyer

Plenary Session 7: FL and CLL Evolution and Transformation

10:30 am-12:00 pm | America Ballroom North and Center

Session Chair: Catherine J. Wu, Dana Farber Cancer Institute, Boston, MA

- | | |
|-------------|---|
| 10:30-10:50 | Human genetic studies: CLL and transformation
Catherine J. Wu, Dana Farber Cancer Institute, Boston, MA |
| 10:50-10:55 | Q&A / Discussion |
| 10:55-11:15 | Understanding CLL and Richter's syndrome biology through mouse models of human genetics
Elisa ten Hacken, Dana Farber Cancer Institute, Boston, MA |
| 11:15-11:20 | Q&A / Discussion |
| 11:20-11:40 | [R] - Follicular lymphoma and transformation
Jessica Okosun, Queen Mary University of London, London, England |
| 11:40-11:45 | Q&A / Discussion |
| 11:45-12:00 | Panel Discussion |

Lunch Available

12:00 pm-1:30 pm | America Ballroom South

Special Session 3: T-cell Lymphomas

12:30 pm-1:30 pm | America Ballroom North and Center

Session Chair: Teresa Palomero, Columbia University, New York, NY

- | | |
|-------------|--|
| 12:30-12:45 | Genomic alterations and mouse models in PTCL
Teresa Palomero, Columbia University, New York, NY |
| 12:45-12:50 | Q&A / Discussion |
| 12:50-1:05 | The role of PD1 in t cell lymphomas
Jaehyuk Choi, Northwestern University, Chicago, IL |
| 1:05-1:10 | Q&A / Discussion |
| 1:10-1:30 | Panel Discussion |

Third AACR International Meeting
Advances in Malignant Lymphoma:
Maximizing the Basic-Translational Interface for Clinical Application
In cooperation with the International Conference on Malignant Lymphoma (ICML)
In association with *Blood Cancer Discovery*
June 23-26, 2022 | Westin Copley Place | Boston, MA

Plenary Session 8: New Technologies

1:45 pm-3:15 pm | America Ballroom North and Center

Session Chair: Kojo S.J. Elenitoba-Johnson, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

- | | |
|-----------|---|
| 1:45-2:05 | Lost in ubiquitination, found by mass spectrometry: Novel proteolytic mechanisms implicated in lymphoma transformation
Kojo S.J. Elenitoba-Johnson, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA |
| 2:05-2:10 | Q&A / Discussion |
| 2:10-2:30 | A multi-scale, multiomic atlas of human normal and follicular lymphoma lymph nodes
Andrea Radtke, National Institute of Allergy and Infectious Diseases, Bethesda, MD |
| 2:30-2:35 | Q&A / Discussion |
| 2:35-2:55 | [R] -Elucidation of lymphoma biology by proteogenomics
Thomas Oellerich, Goethe University Hospital, Frankfurt, Germany |
| 2:55-3:00 | Q&A / Discussion |
| 3:00-3:15 | Panel Discussion |

Break

3:15 pm-3:30 pm | America Ballroom Foyer

Plenary Session 9: Immune Evasion in Hodgkin and Non-Hodgkin Lymphomas

3:30 pm-5:00 pm | America Ballroom North and Center

Session Chair: Margaret A. Shipp, Dana Farber Cancer Institute, Boston, MA

- | | |
|-----------|---|
| 3:30-3:50 | Genetic bases of immune evasion in lymphoid malignancies
Margaret A. Shipp, Dana Farber Cancer Institute, Boston, MA |
| 3:50-3:55 | Q&A / Discussion |
| 3:55-4:15 | New imaging approaches to characterize the intact tumor microenvironment
Scott J. Rodig, Brigham and Women's Hospital, Boston, MA |
| 4:15-4:20 | Q&A / Discussion |
| 4:20-4:40 | The DLBCL immune landscape: Evidence for immune surveillance, evasion, and exclusion
Justin P. Kline, University of Chicago, Chicago, IL |
| 4:40-4:45 | Q&A / Discussion |

Third AACR International Meeting
Advances in Malignant Lymphoma:
Maximizing the Basic-Translational Interface for Clinical Application
 In cooperation with the International Conference on Malignant Lymphoma (ICML)
 In association with *Blood Cancer Discovery*
 June 23-26, 2022 | Westin Copley Place | Boston, MA

4:45-5:00 Panel Discussion

Break

5:00 pm-5:30 pm | America Ballroom Foyer

Special Session 4: Industry Roundtable

5:30 pm-6:30 pm | America Ballroom North and Center

Session Chair: Anas Younes, AstraZeneca, New York, NY

5:30-5:40 [R] - Adam S. Crystal, C4 Therapeutics, Watertown, MA

5:40-5:45 Q&A / Discussion

5:45-5:55 Gwenn Hansen, Nurix Therapeutics, Inc., San Francisco, CA

5:55-6:00 Q&A / Discussion

6:00-6:10 Clinical experience with off-the-shelf iPSC derived cell therapies in hematologic malignancies

Yu-Waye (Wayne) Chu, Fate Therapeutics, San Diego, CA

6:10-6:15 Q&A / Discussion

6:15-6:30 Panel Discussion

SUNDAY, JUNE 26

Breakfast

7:00 am-8:00 am | America Ballroom South

Special Session 5: AYA Lymphomas

7:30 am-8:30 am | America Ballroom North and Center

Session Chair: Andrew M. Evens, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

7:30-7:45 Pathology of AYA lymphomas: Creating a roadmap for translational discovery
 Megan S. Lim, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA

7:45-7:50 Q&A / Discussion

7:50-8:05 Unmet clinical research questions in AYA lymphomas
 Jamie E. Flerlage, St. Jude Children's Research Hospital, Memphis, TN

8:05-8:10 Q&A / Discussion

8:10-8:30 Panel Discussion

Third AACR International Meeting
Advances in Malignant Lymphoma:
Maximizing the Basic-Translational Interface for Clinical Application
In cooperation with the International Conference on Malignant Lymphoma (ICML)
In association with *Blood Cancer Discovery*
June 23-26, 2022 | Westin Copley Place | Boston, MA

Break

8:30 am-8:45 am | America Ballroom Foyer

Plenary Session 10: Metabolism and Immunometabolism in Lymphoid Malignancies: A New Target?

8:45 am-10:15 am | America Ballroom North and Center

Session Chair: Ari M. Melnick, Weill Cornell Medical College / Cornell University, New York, NY

8:45-9:05 Metabolic communication between the lymphoma microenvironments

Leandro C. Cerchietti, Weill Cornell Medicine, New York, NY

9:05-9:10 Q&A / Discussion

9:10-9:30 Title to be announced

Nika N. Danial, Dana-Farber Cancer Institute, Boston, MA

9:30-9:35 Q&A / Discussion

9:35-9:55 Multi-omic analysis reveals B-cell stimulus-specific oncogenic pathway responses and targets

Benjamin E. Gewurz, Brigham and Women's Hospital, Boston, MA

9:55-10:00 Q&A / Discussion

10:00-10:15 Panel Discussion

Break

10:15 am-10:30 am | America Ballroom Foyer

Plenary Session 11: Moving Beyond the Basics in PET: Functional Imaging in Lymphoma

10:30 am-12:00 pm | America Ballroom North and Center

Session Chair: Judith Trotman, University of Sydney, Sydney, Australia

10:30-10:50 Recent and future developments in PET imaging of lymphoma

Heiko Schöder, Memorial Sloan Kettering Cancer Center, New York, NY

10:50-10:55 Q&A / Discussion

10:55-11:15 FDG-PET in FL: Staging, response assessment, and beyond

Stefano Luminari, University of Modena and Reggio Emilia, Modena, Italy

11:15-11:20 Q&A / Discussion

11:20-11:40 PET in diffuse large B cell lymphoma

Judith Trotman, University of Sydney, Sydney, Australia

11:40-11:45 Q&A / Discussion

11:45-12:00 Panel Discussion

Third AACR International Meeting
Advances in Malignant Lymphoma:
Maximizing the Basic-Translational Interface for Clinical Application
In cooperation with the International Conference on Malignant Lymphoma (ICML)
In association with *Blood Cancer Discovery*
June 23-26, 2022 | Westin Copley Place | Boston, MA

Break

12:00 pm-12:15 pm | America Ballroom Foyer

Plenary Session 12: Exploiting NK Cell-therapy in Lymphomas

12:15 pm-1:45 pm | America Ballroom North and Center

Session Chair: Riccardo Dalla-Favera, Columbia University, New York, NY

- | | |
|-------------|--|
| 12:15-12:35 | Development of nicotinamide enhanced NK cell therapeutics for lymphoma
Veronika S. Bachanova, University of Minnesota, Minneapolis, MN |
| 12:35-12:40 | Q&A / Discussion |
| 12:40-1:00 | Driving innate recognition and engineering memory-like NK cells in lymphoma
Melissa M. Berrien-Elliott, Washington University School of Medicine, St. Louis, MO |
| 1:00-1:05 | Q&A / Discussion |
| 1:05-1:25 | IL-21 expanded, off the shelf, third-party NK cells: Novel therapies for lymphoma
John C. Reneau, The Ohio State University Wexner Medical Center, Columbus, OH |
| 1:25-1:30 | Q&A / Discussion |
| 1:30-1:45 | Panel Discussion |

Closing Comments and Departure

1:45 pm | America Ballroom North and Center

Riccardo Dalla-Favera, Columbia University, New York, NY